Editas Medicine (EDIT) vs Protalix BioTherapeutics (DE) (PLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Protalix BioTherapeutics (DE) (PLX) has outperformed Editas Medicine (EDIT) over the past year, gaining 65.7% versus a loss of 32.2%. Over five years, PLX leads with a +192.9% price change compared with -94.9% for EDIT. Editas Medicine is the larger company by market cap ($253.1 million vs $244.5 million), about 1.0 times the size.
Protalix BioTherapeutics (DE) converts more of its revenue into profit, with a net margin of -12.5% versus -395.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | PLX |
|---|---|---|
| Share price | $1.64 | $2.90 |
| Market cap | $253.12M | $244.52M |
| 1-day change | -4.09% | -5.23% |
| YTD return | -20.00% | +61.11% |
| 1-year return | -32.23% | +65.71% |
| 5-year return | -94.93% | +192.93% |
| P/E ratio (TTM) | — | 12.08 |
| Forward P/E | — | 4.68 |
| EPS (TTM) | $-0.54 | $0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $40.52M | $52.74M |
| Revenue growth (YoY) | +25.39% | -1.23% |
| Net income (latest FY) | $-160.06M | $-6.60M |
| Gross margin | — | 48.82% |
| Operating margin | -394.89% | -10.43% |
| Net margin | -395.01% | -12.52% |
| 52-week high | $3.94 | $3.19 |
| 52-week low | $1.63 | $1.65 |
| Distance from 52-week high | -58.38% | -9.09% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +271.95% | +313.79% |
| Average volume | 2.63M | 903.48K |
| Shares outstanding | 154.34M | 84.32M |
| Employees | 87 | 226 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PLX has outperformed EDIT by 97.9 percentage points over the past year.
- Protalix BioTherapeutics (DE) is more profitable, keeping -12.5 cents of every revenue dollar as net income versus -395.0 cents for Editas Medicine.
- Editas Medicine grew revenue faster in its latest fiscal year (+25.39% vs -1.23%).
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About Protalix BioTherapeutics (DE)
PLX stock →Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 226 employees
EDIT vs PLX FAQ
Which is bigger, Editas Medicine or Protalix BioTherapeutics (DE)?
Editas Medicine (EDIT) is larger, with a market capitalization of $253.12M compared with $244.52M for Protalix BioTherapeutics (DE) (PLX).
Which stock has performed better over the past year, EDIT or PLX?
PLX returned +65.71% over the past 12 months, compared with -32.23% for EDIT (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and Protalix BioTherapeutics (DE) in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.